OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX - Free Report) in a research report released on Saturday. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a "buy" rating and set a $4.25 price objective on shares of OncoCyte in a report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $4.06.

OncoCyte Trading Down 1.0 %

Shares of NASDAQ:OCX opened at $3.00 on Friday. The stock has a 50 day moving average of $3.08 and a 200 day moving average of $2.95. OncoCyte has a 12-month low of $2.08 and a 12-month high of $4.34.

OncoCyte (NASDAQ:OCX - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. The company had revenue of $0.10 million for the quarter.

Insider Transactions at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the company's stock in a transaction dated Wednesday, October 2nd. The shares were acquired at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the transaction, the insider now owns 6,244,405 shares of the company's stock, valued at $18,420,994.75. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of OncoCyte stock in a transaction that occurred on Wednesday, October 2nd. The stock was purchased at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the purchase, the insider now directly owns 6,244,405 shares in the company, valued at $18,420,994.75. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Andrea S. James bought 33,670 shares of the stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average price of $2.97 per share, with a total value of $99,999.90. Following the completion of the purchase, the chief financial officer now owns 33,670 shares of the company's stock, valued at $99,999.90. The disclosure for this purchase can be found here. Corporate insiders own 1.58% of the company's stock.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.